- JP-listed companies
- Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co., Ltd.JP:4577
Market cap
¥35B
P/E ratio
11x
| May 31, 2013 | May 31, 2014 | May 31, 2015 | May 31, 2016 | May 31, 2017 | May 31, 2018 | May 31, 2019 | May 31, 2020 | May 31, 2021 | May 31, 2022 | May 31, 2023 | May 31, 2024 | |
| Profit (loss) before income taxes | 2,608 | 2,869 | 3,373 | 3,426 | 3,885 | 4,263 | 4,619 | 5,595 | 5,874 | 6,720 | 5,076 | 4,218 |
| Depreciation | 2,569 | 2,445 | 2,440 | 2,643 | 2,818 | 2,853 | 2,853 | 2,950 | 3,154 | 3,313 | 3,870 | 3,659 |
| Loss on retirement of non-current assets | 60 | 20 | 168 | 7 | 85 | 1 | 0 | 11 | 8 | 33 | 17 | 48 |
| Loss on tax purpose reduction entry of non-current assets | 1 | 8 | - | 3 | 200 | - | 158 | 146 | 100 | 23 | - | 117 |
| Increase (decrease) in allowance for doubtful accounts | -16 | -5 | -6 | 41 | -50 | -5 | -8 | -5 | -12 | -15 | -3 | -1 |
| Increase (decrease) in provision for bonuses | 1 | 18 | 6 | 21 | -53 | 1 | -2 | 1 | 4 | 2 | 3 | 4 |
| Increase (decrease) in retirement benefit liability | - | -34 | 67 | -11 | 274 | 24 | 16 | 5 | 71 | -68 | 41 | -230 |
| Increase (decrease) in provision for share awards for directors (and other officers) | - | - | - | - | - | - | - | - | - | - | 10 | 10 |
| Interest and dividend income | -38 | -61 | -67 | -59 | -67 | -67 | -73 | -69 | -64 | -56 | -58 | -66 |
| Rental income | -19 | -17 | -17 | -21 | -21 | -18 | -14 | -12 | -15 | -14 | -14 | -15 |
| Insurance claim income | - | - | - | - | -67 | -21 | - | - | - | -57 | - | -17 |
| Interest expenses | 126 | 87 | 58 | 40 | 29 | 24 | 21 | 12 | 8 | 9 | 12 | 41 |
| Subsidy income | -2 | -8 | - | -18 | -225 | -9 | -217 | -153 | -120 | -23 | -12 | -135 |
| Foreign exchange losses (gains) | - | 0 | -9 | 10 | -1 | 6 | 11 | -1 | 2 | -28 | -12 | -78 |
| Loss (gain) on sale of investment securities | - | -30 | -77 | - | - | - | - | -150 | -4 | -246 | 67 | -326 |
| Loss (gain) on valuation of investment securities | - | - | - | - | - | 10 | 81 | 15 | 3 | 199 | 20 | - |
| Decrease (increase) in trade receivables | -1,093 | -2,682 | -962 | 830 | -711 | 458 | 948 | -3,369 | 2,723 | -3,299 | -1,502 | 2,221 |
| Decrease (increase) in inventories | -599 | -419 | -916 | -1,632 | -1,509 | -815 | -751 | -2,075 | -3,609 | -1,041 | -1,413 | -2,640 |
| Increase (decrease) in trade payables | 486 | 1,215 | 998 | -1,111 | -91 | 737 | 335 | 1,229 | -765 | 22 | 538 | 802 |
| Decrease (increase) in consumption taxes refund receivable | - | - | - | - | - | - | - | - | - | - | - | -1,292 |
| Other, net | -155 | 93 | -179 | -196 | 967 | -372 | 60 | 764 | -472 | 670 | -126 | -52 |
| Subtotal | 3,716 | 3,528 | 4,866 | 4,290 | 5,457 | 7,045 | 8,020 | 4,874 | 7,082 | 6,141 | 6,514 | 6,265 |
| Interest and dividends received | 38 | 61 | 67 | 59 | 67 | 67 | 73 | 69 | 64 | 56 | 58 | 66 |
| Interest paid | -127 | -87 | -57 | -41 | -28 | -24 | -20 | -11 | -7 | -9 | -13 | -40 |
| Subsidies received | 2 | 8 | - | 18 | 225 | 9 | 217 | 153 | 120 | 23 | 12 | 135 |
| Income taxes paid | -1,085 | -725 | -1,129 | -1,412 | -767 | -1,678 | -1,431 | -811 | -2,088 | -1,924 | -2,411 | -1,265 |
| Insurance claim income received | - | - | - | - | - | - | - | - | - | 57 | - | 17 |
| Other, net | -3 | 18 | -8 | 34 | 117 | 46 | 30 | 32 | 12 | 26 | -5 | 4 |
| Net cash provided by (used in) operating activities | 2,541 | 2,745 | 3,739 | 2,949 | 5,070 | 5,465 | 6,888 | 4,306 | 5,183 | 4,370 | 4,155 | 5,182 |
| Purchase of property, plant and equipment | -1,859 | -2,335 | -4,919 | -3,949 | -2,992 | -3,822 | -3,630 | -2,731 | -6,318 | -4,627 | -5,505 | -6,220 |
| Purchase of intangible assets | - | - | - | - | - | -52 | -33 | -42 | -31 | -106 | -51 | -56 |
| Proceeds from sale of investment securities | 7 | 54 | 101 | 8 | - | - | - | 175 | 5 | 256 | - | 335 |
| Other, net | -96 | -51 | -52 | -25 | -20 | -16 | 8 | -6 | 20 | 77 | -8 | 10 |
| Net cash provided by (used in) investing activities | -2,237 | -2,163 | -4,595 | -4,015 | -3,012 | -3,833 | -3,867 | -2,681 | -6,324 | -4,400 | -5,566 | -5,930 |
| Proceeds from long-term borrowings | 3,150 | 2,000 | 1,800 | 2,500 | 2,300 | 2,500 | 1,000 | - | 2,000 | 1,500 | 3,000 | 4,000 |
| Repayments of long-term borrowings | -2,775 | -2,669 | -2,632 | -2,622 | -2,335 | -2,265 | -2,039 | -1,852 | -1,712 | -1,444 | -1,638 | -2,029 |
| Dividends paid | -268 | -296 | -466 | -375 | -375 | -413 | -451 | -502 | -658 | -660 | -931 | -907 |
| Purchase of treasury shares | -0 | -0 | -8 | -2 | -1 | -1 | -0 | -0 | - | - | -110 | -1,176 |
| Repayments of lease liabilities | -365 | -381 | -266 | -167 | -44 | -15 | -8 | -5 | -2 | -1 | -5 | -70 |
| Proceeds from issuance of shares resulting from exercise of share acquisition rights | - | - | - | - | - | - | - | 2,001 | 1,799 | 1,514 | 308 | - |
| Payments from the gain of own stock acquisition rights | - | - | - | - | - | - | - | - | - | - | -6 | - |
| Net cash provided by (used in) financing activities | 1,690 | -2,065 | 503 | 526 | -1,778 | -1,544 | -2,898 | -350 | 1,425 | 989 | 616 | -183 |
| Effect of exchange rate change on cash and cash equivalents | 132 | 71 | -15 | -28 | -14 | 5 | -15 | -10 | 6 | 48 | 20 | 51 |
| Net increase (decrease) in cash and cash equivalents | 2,126 | -1,413 | -367 | -568 | 266 | 94 | 108 | 1,265 | 289 | 1,008 | -774 | -879 |